Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of nipocalimab in adults with moderate to severe systemic lupus erythematosus
MOH_2026-03-02_015695Phase 3Recruiting
- Sponsor
- Johnson & Johnson
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing IMAAVY with Placebo (2 arms). Started Jan 2026; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2026-03-02_015695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-02_015695.